Published in Transfusion on May 14, 2009
Quality and Safety in Blood Supply in 2010. Transfus Med Hemother (2010) 1.17
Pilot studies for development of an HIV subtype panel for surveillance of global diversity. AIDS Res Hum Retroviruses (2012) 0.95
Screening acute HIV infections among Chinese men who have sex with men from voluntary counseling & testing centers. PLoS One (2011) 0.95
Screening Donated Blood for Transfusion Transmitted Infections by Serology along with NAT and Response Rate to Notification of Reactive Results: An Indian Experience. J Blood Transfus (2014) 0.91
Pathogen inactivation technologies for cellular blood components: an update. Transfus Med Hemother (2014) 0.90
Factors in enhancing blood safety by nucleic acid technology testing for human immunodeficiency virus, hepatitis C virus and hepatitis B virus. Asian J Transfus Sci (2014) 0.87
Quarantine Plasma: Quo vadis? Transfus Med Hemother (2010) 0.87
Interpretation of real-time PCR results for hepatitis C virus RNA when viral load is below quantification limits. J Clin Microbiol (2011) 0.84
Hepatitis B virus infection among first-time blood donors in Italy: prevalence and correlates between serological patterns and occult infection. Blood Transfus (2013) 0.82
Molecular virology in transfusion medicine laboratory. Blood Transfus (2012) 0.79
Half a decade of mini-pool nucleic acid testing: Cost-effective way for improving blood safety in India. Asian J Transfus Sci (2014) 0.79
Occult hepatitis B virus infection among blood donors in Colombia. Virol J (2014) 0.78
Evaluation of Risk Minimisation Measures for Blood Components - Based on Reporting Rates of Transfusion-Transmitted Reactions (1997-2013). Transfus Med Hemother (2015) 0.78
Solvent/Detergent Virally Inactivated Serum Eye Drops Restore Healthy Ocular Epithelium in a Rabbit Model of Dry-Eye Syndrome. PLoS One (2016) 0.75
'Sterility Testing of Blood Components and Advanced Therapy Medicinal Products' (Munich, April 29, 2010) Organized by the DGTI Section 'Safety in Hemotherapy' - Meeting Report. Transfus Med Hemother (2011) 0.75
Implementation of an HIV-1 Triple-Target NAT Assay in the Routine Screening at Three German Red Cross Blood Centres. Transfus Med Hemother (2016) 0.75
Development of an HIV-1 Subtype Panel in China: Isolation and Characterization of 30 HIV-1 Primary Strains Circulating in China. PLoS One (2015) 0.75
Comment on: One window-period donation in two years of individual donor-nucleic acid test screening for hepatitis B, hepatitis C and human immunodeficiency virus. Rev Bras Hematol Hemoter (2013) 0.75
Human Immunodeficiency Virus (HIV). Transfus Med Hemother (2016) 0.75
Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies. J Neurol Neurosurg Psychiatry (2012) 1.66
A multi-centre collaborative study on the potency estimation of ReFacto. Thromb Haemost (2003) 1.45
Infectivity of blood products from donors with occult hepatitis B virus infection. Transfusion (2013) 1.43
[Suspected cases of severe side effects after infliximab (Remicade) in Germany]. Med Klin (Munich) (2003) 1.38
Vaccination safety update. Dtsch Arztebl Int (2008) 1.26
Quality and Safety in Blood Supply in 2010. Transfus Med Hemother (2010) 1.17
Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase. Transfusion (2002) 1.16
International registry on factor XIII deficiency: a basis formed mostly on European data. Thromb Haemost (2007) 1.10
Report on Notifications Pursuant to section sign21 German Transfusion Act for 2007. Transfus Med Hemother (2010) 1.05
Blood screening nucleic acid amplification tests for human immunodeficiency virus Type 1 may require two different amplification targets. Transfusion (2011) 1.04
Transfusion-Transmitted Bacterial Infections - Haemovigilance Data of German Blood Establishments (1997-2010). Transfus Med Hemother (2011) 1.03
First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in Germany. Transfusion (2009) 1.02
A(H1N1)v2009: a controlled observational prospective cohort study on vaccine safety in pregnancy. Vaccine (2012) 0.96
Impact of vCJD on blood supply. Biologicals (2007) 0.95
Identification of prothrombin as a major thrombogenic agent in prothrombin complex concentrates. Blood Coagul Fibrinolysis (2004) 0.92
Effect of Safety Measures on Bacterial Contamination Rates of Blood Components in Germany. Transfus Med Hemother (2011) 0.90
West Nile virus and blood product safety in Germany. J Med Virol (2008) 0.89
The development of standardized case definitions and guidelines for adverse events following immunization. Vaccine (2007) 0.88
Multicenter performance evaluation of a transcription-mediated amplification assay for screening of human immunodeficiency virus-1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA in blood donations. Transfusion (2005) 0.87
Management of blood supplies during an influenza pandemic. Transfusion (2009) 0.87
Hepatitis E Virus. Transfus Med Hemother (2008) 0.86
Malaria. Transfus Med Hemother (2008) 0.86
Report on Notifications Pursuant to §21 German Transfusion Act for 2008 and 2009. Transfus Med Hemother (2011) 0.86
The hyaluronan-binding serine protease from human plasma cleaves HMW and LMW kininogen and releases bradykinin. Biol Chem (2002) 0.86
Influenza Virus. Transfus Med Hemother (2007) 0.85
Arbobacteria - Pathogens Transmittable by Arthropods. Transfus Med Hemother (2008) 0.85
Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools. Transfusion (2008) 0.84
Human Cytomegalovirus (HCMV) - Revised. Transfus Med Hemother (2010) 0.83
Neopterin levels during the early phase of human immunodeficiency virus, hepatitis C virus, or hepatitis B virus infection. Transfusion (2006) 0.83
Risk of Guillain-Barré syndrome following pandemic influenza A(H1N1) 2009 vaccination in Germany. Pharmacoepidemiol Drug Saf (2014) 0.83
Inhibition of bFGF/EGF-dependent endothelial cell proliferation by the hyaluronan-binding protease from human plasma. Eur J Cell Biol (2004) 0.82
An update of the mutation profile of Factor 13 A and B genes. Blood Rev (2011) 0.82
Impact of rotavirus vaccination in regions with low and moderate vaccine uptake in Germany. Hum Vaccin Immunother (2012) 0.82
A highly sensitive fluorometric assay for determination of human coagulation factor XIII in plasma. Anal Biochem (2007) 0.81
West nile virus. Transfus Med Hemother (2013) 0.81
Charge analysis of N-glycans from human recombinant coagulation factor VIII and human FVIII standards. Thromb Haemost (2004) 0.81
Role of regulatory agencies. Biologicals (2009) 0.81
Prothrombin overload causes thromboembolic complications in prothrombin complex concentrates: in vitro and in vivo evidence. Thromb Haemost (2005) 0.80
How safe is safe: new human immunodeficiency virus Type 1 variants missed by nucleic acid testing. Transfusion (2013) 0.80
Inducible expression of tissue factor in small-cell lung cancer: impact on morphology and matrix metalloproteinase secretion. J Cancer Res Clin Oncol (2012) 0.80
A retrospective population-based study on seizures related to childhood vaccination. Epilepsia (2011) 0.80
Consistency of quantitation of HCV genotype 4 from egypt across three HCV-RNA amplification assays. J Med Virol (2008) 0.80
Orthopox Viruses: Infections in Humans. Transfus Med Hemother (2010) 0.79
The hyaluronic acid-binding protease: a novel vascular and inflammatory mediator? Int Immunopharmacol (2007) 0.78
Hepatitis E Virus. Transfus Med Hemother (2015) 0.78
Parvovirus B19 - Revised. Transfus Med Hemother (2010) 0.77
Evaluation of Quality Parameters for Cord Blood Donations. Transfus Med Hemother (2009) 0.77
A secreted metallo protease from Aeromonas hydrophila exhibits prothrombin activator activity. Blood Coagul Fibrinolysis (2004) 0.76
Comparison of two von Willebrand factor collagen-binding assays with different binding affinities for low, medium, and high multimers of von Willebrand factor. Semin Thromb Hemost (2002) 0.76
Quality of therapeutic plasma-requirements for marketing authorization. Thromb Res (2002) 0.76
Factor VIII determination in patient's plasma and concentrates: a novel test equally suited for both matrices. Blood Coagul Fibrinolysis (2003) 0.76
Factor XIIIa generation assay: a tool for studying factor XIII function in plasma. Anal Biochem (2013) 0.76
Arbonematodes - nematode infections transmissible by arthropods: arbeitskreis blut, untergruppe «bewertung blutassoziierter krankheitserreger»*. Transfus Med Hemother (2013) 0.75
Still in Focus: Assessment of Blood-Borne Pathogens. Transfus Med Hemother (2009) 0.75
Nonfebrile seizures after mumps, measles, rubella, and varicella-zoster virus combination vaccination with detection of measles virus RNA in serum, throat, and urine. Clin Vaccine Immunol (2013) 0.75
Good clinical practice in the European Union. Hum Gene Ther (2008) 0.75
The Wildbad Kreuth initiative: European current practices and recommendations for optimal use of blood components. Biologicals (2011) 0.75
Induction of intracellular signalling in human endothelial cells by the hyaluronan-binding protease involves two distinct pathways. Biol Chem (2006) 0.75
[Marketing authorization for pharmaceuticals: the necessity of European collaboration]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz (2008) 0.75
Anaphylaxis After Immunization of Children and Adolescents in Germany. Pediatr Infect Dis J (2016) 0.75
A novel assay for factor XIII based on cross-linking of synthetic peptides: analysis of different substrates. Blood Coagul Fibrinolysis (2006) 0.75